Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?
Rituximab is currently approved for patients affected by moderate-to-severe pemphigus vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The standard rituximab dosing regimens, originally established for B-cell non-Hodgkin’s lymphomas, have been recognized to exceed...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Antibodies |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4468/13/1/4 |
| _version_ | 1797242313827680256 |
|---|---|
| author | Christian Ciolfi Jacopo Tartaglia Mauro Alaibac |
| author_facet | Christian Ciolfi Jacopo Tartaglia Mauro Alaibac |
| author_sort | Christian Ciolfi |
| collection | DOAJ |
| description | Rituximab is currently approved for patients affected by moderate-to-severe pemphigus vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The standard rituximab dosing regimens, originally established for B-cell non-Hodgkin’s lymphomas, have been recognized to exceed the effective dose required for inducing B-cell depletion, considering that the B-cell burden in pemphigus vulgaris is considerably lower than in lymphoproliferative disorders. We herein report our experience with very ultra-low-dose rituximab in two patients affected by pemphigus vulgaris. |
| first_indexed | 2024-04-24T18:37:15Z |
| format | Article |
| id | doaj.art-e7e7f435fcad46f1b60ae4f9514f12fd |
| institution | Directory Open Access Journal |
| issn | 2073-4468 |
| language | English |
| last_indexed | 2024-04-24T18:37:15Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Antibodies |
| spelling | doaj.art-e7e7f435fcad46f1b60ae4f9514f12fd2024-03-27T13:18:17ZengMDPI AGAntibodies2073-44682024-01-01131410.3390/antib13010004Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris?Christian Ciolfi0Jacopo Tartaglia1Mauro Alaibac2Dermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, ItalyDermatology Unit, Department of Medicine (DIMED), University of Padua, 35121 Padua, ItalyRituximab is currently approved for patients affected by moderate-to-severe pemphigus vulgaris, a severe autoimmune blistering skin disease that can be life-threatening. The standard rituximab dosing regimens, originally established for B-cell non-Hodgkin’s lymphomas, have been recognized to exceed the effective dose required for inducing B-cell depletion, considering that the B-cell burden in pemphigus vulgaris is considerably lower than in lymphoproliferative disorders. We herein report our experience with very ultra-low-dose rituximab in two patients affected by pemphigus vulgaris.https://www.mdpi.com/2073-4468/13/1/4pemphigus vulgarisrituximabvery ultra-low doseinfusion reactionscost-effectiveness |
| spellingShingle | Christian Ciolfi Jacopo Tartaglia Mauro Alaibac Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? Antibodies pemphigus vulgaris rituximab very ultra-low dose infusion reactions cost-effectiveness |
| title | Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? |
| title_full | Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? |
| title_fullStr | Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? |
| title_full_unstemmed | Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? |
| title_short | Is It Time to Reconsider Rituximab Dosing Regimens for Pemphigus Vulgaris? |
| title_sort | is it time to reconsider rituximab dosing regimens for pemphigus vulgaris |
| topic | pemphigus vulgaris rituximab very ultra-low dose infusion reactions cost-effectiveness |
| url | https://www.mdpi.com/2073-4468/13/1/4 |
| work_keys_str_mv | AT christianciolfi isittimetoreconsiderrituximabdosingregimensforpemphigusvulgaris AT jacopotartaglia isittimetoreconsiderrituximabdosingregimensforpemphigusvulgaris AT mauroalaibac isittimetoreconsiderrituximabdosingregimensforpemphigusvulgaris |